Powerful, Robust and Flexible

Oncolytic viruses are designed to infect and kill tumor cells and enhance a patient’s own immune response to provide further antitumor activity. Our vesicular stomatitis virus (VSV) technology can be administered intravenously in a clinical setting and is a strong platform for developing multiple targeted oncolytic virus therapies:

• Powerful: Vyriad has developed proprietary technology to rapidly engineer VSV to boost its anticancer activity and to allow noninvasive monitoring in patients.
• Robust: We are evaluating Voyager-V1 as a combination therapy in the clinic and jointly designing and validating a new generation of precision targeted VSV therapies in partnership with Regeneron Pharmaceuticals.
• Flexible: Most patients do not have pre-existing antiviral antibodies to VSV, making oncolytic VSV appropriate for diverse cancer indications.

The Voyager-V1 Clinical Program

Voyager-V1, currently being tested in partnership with Regeneron, is our lead clinical asset based on the VSV platform. Voyager-V1 is designed for enhanced safety, efficacy, and traceability. Through the inclusion of the interferon beta gene, Voyager-V1 is able to replicate quickly in cancer cells without damaging healthy cells, recruit cancer-fighting immune cells to the tumor, and secrete a measurable reporter protein into the blood.

Voyager-V1 also includes an iodine transporter NIS gene that facilitates tracking of the virus as it spreads to cancer cells throughout the body using single-photon emission computed tomography (SPECT) or positron emission tomography (PET) imaging.

Voyager-V1 Sees Success in Early Trials

Voyager-VI is in clinical development as a monotherapy and in combination with several other immunotherapies including immune checkpoint inhibitors (anti-PD-1 and anti-PD-L1 monoclonal antibodies) that prevent one of cancer’s main defenses against T cell attack.

In a phase 1 clinical trial of Voyager-V1 in patients with disseminated peripheral T cell lymphoma, more than half of patients who received the investigational therapy achieved a response, and a third of patients achieved a complete response lasting five months to thirty months.